Drug Profile


Alternative Names: Absorcol; Ezedoc; Ezetrol; HGP1404; SCH 58235; Zetia

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Propanols; Small molecules
  • Mechanism of Action Cholesterol absorption inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipoproteinaemia type II; Sitosterolaemia
  • Preregistration Acute coronary syndromes

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for ezetimibe in Europe and Japan (Merck Annual report 2016)
  • 12 Dec 2016 First generic equivalent of ezetimibe available in USA for Hypercholesterolaemia
  • 15 Feb 2016 Merck receives complete response letter from the FDA for ezetimibe in Acute coronary syndromes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top